mantle cell lymphoma

Summary

Summary: A rare form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the cyclin D1 gene (GENES, BCL-1).

Top Publications

  1. ncbi Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma
    Veronica Fernandez
    Hematopathology Section, Department of Pathology, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer and Department of Hematology, Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain
    Cancer Res 70:1408-18. 2010
  2. pmc microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma
    Jian Jun Zhao
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Blood 115:2630-9. 2010
  3. pmc Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
    Brian G Till
    Clinical Research Division of the Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 112:2261-71. 2008
  4. ncbi The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma
    Andreas Rosenwald
    The Lymphoma Leukemia Molecular Profiling Project, National Cancer Institute NIH, Bethesda, MD, USA
    Cancer Cell 3:185-97. 2003
  5. ncbi Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma
    Jessica Dal Col
    Cancer Bio Immunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico CRO, Istituto di Ricovero e Cura a Caratiere Scientifico IRCCS National Cancer Institute, Aviano, Italy
    Blood 111:5142-51. 2008
  6. pmc FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma
    Qing Liu
    Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, USA
    Clin Cancer Res 16:3182-92. 2010
  7. pmc Constitutive activation of the Wnt canonical pathway in mantle cell lymphoma
    Pascal Gelebart
    Department of Laboratory Medicine and Pathology, Cross Cancer Institute and University of Alberta, Edmonton, AB
    Blood 112:5171-9. 2008
  8. ncbi MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma
    Yoko Tabe
    Hematopathology Section, Laboratory of Pathology, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 15:933-42. 2009
  9. ncbi Improvement of overall survival in advanced stage mantle cell lymphoma
    Annina Herrmann
    Department of Internal Medicine III, University of Munich, Germany
    J Clin Oncol 27:511-8. 2009
  10. pmc ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors
    Chris T Williamson
    Department of Biochemistry and Molecular Biology, University of Calgary, Calgary, Alberta, Canada
    Mol Cancer Ther 9:347-57. 2010

Detail Information

Publications331 found, 100 shown here

  1. ncbi Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma
    Veronica Fernandez
    Hematopathology Section, Department of Pathology, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer and Department of Hematology, Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain
    Cancer Res 70:1408-18. 2010
    b>Mantle cell lymphoma (MCL) is typically a very aggressive disease with poor outcomes, but some cases display an indolent behavior that might not necessitate treatment at diagnosis...
  2. pmc microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma
    Jian Jun Zhao
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Blood 115:2630-9. 2010
    b>Mantle cell lymphoma (MCL) is one of the most aggressive B-cell lymphomas. Although several protein-coding genes are altered, expression signature and importance of microRNA (miRNA) have not been well documented in this malignancy...
  3. pmc Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
    Brian G Till
    Clinical Research Division of the Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 112:2261-71. 2008
    ..a proof-of-concept clinical trial in which patients with relapsed or refractory indolent B-cell lymphoma or mantle cell lymphoma were treated with autologous T cells genetically modified by electroporation with a vector plasmid encoding ..
  4. ncbi The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma
    Andreas Rosenwald
    The Lymphoma Leukemia Molecular Profiling Project, National Cancer Institute NIH, Bethesda, MD, USA
    Cancer Cell 3:185-97. 2003
    We used gene expression profiling to establish a molecular diagnosis of mantle cell lymphoma (MCL), to elucidate its pathogenesis, and to predict the length of survival of these patients...
  5. ncbi Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma
    Jessica Dal Col
    Cancer Bio Immunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico CRO, Istituto di Ricovero e Cura a Caratiere Scientifico IRCCS National Cancer Institute, Aviano, Italy
    Blood 111:5142-51. 2008
    Functional characterization of signaling pathways that critically control mantle cell lymphoma (MCL) cell growth and survival is relevant to designing new therapies for this lymphoma...
  6. pmc FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma
    Qing Liu
    Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, USA
    Clin Cancer Res 16:3182-92. 2010
    Despite the progress that has been made in the treatment of mantle cell lymphoma (MCL), all patients invariably relapse with the currently available therapies...
  7. pmc Constitutive activation of the Wnt canonical pathway in mantle cell lymphoma
    Pascal Gelebart
    Department of Laboratory Medicine and Pathology, Cross Cancer Institute and University of Alberta, Edmonton, AB
    Blood 112:5171-9. 2008
    ..We hypothesize that these defects may exist in mantle cell lymphoma (MCL). Both the upstream and downstream aspects of WCP were examined in MCL cell lines and tumors...
  8. ncbi MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma
    Yoko Tabe
    Hematopathology Section, Laboratory of Pathology, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 15:933-42. 2009
    b>Mantle cell lymphoma (MCL) has one of the poorest prognoses of the non-Hodgkin's lymphomas, and novel therapeutic approaches are needed...
  9. ncbi Improvement of overall survival in advanced stage mantle cell lymphoma
    Annina Herrmann
    Department of Internal Medicine III, University of Munich, Germany
    J Clin Oncol 27:511-8. 2009
    ..To explore a potential progress in outcome a historical comparison was performed using data from the Kiel Lymphoma Study Group (KLSG; 1975 to 1986) and the German Low Grade Lymphoma Study Group (GLSG; 1996 to 2004)...
  10. pmc ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors
    Chris T Williamson
    Department of Biochemistry and Molecular Biology, University of Calgary, Calgary, Alberta, Canada
    Mol Cancer Ther 9:347-57. 2010
    ..The ataxia telangiectasia mutated (ATM) gene is altered in several human cancers including mantle cell lymphoma (MCL)...
  11. ncbi Advances in the understanding of mantle cell lymphoma
    Pedro Jares
    Haematopathology Section, Laboratory of Pathology, and Genomics Unit, Hospital Clinic, Institut de Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    Br J Haematol 142:149-65. 2008
    b>Mantle cell lymphoma (MCL) is a well-defined lymphoid neoplasm characterized by a proliferation of mature B lymphocytes expressing CD5 that may show a spectrum of morphological and phenotypic features broader than initially described...
  12. ncbi Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma
    Amanda Psyrri
    Second Department of Internal Medicine, Propaedeutic, University of Athens, University General Hospital Attikon, Haidari, Athens, Greece
    Clin Cancer Res 15:5724-32. 2009
    Activation of phosphatidylinositol 3'-kinase pathway is implicated in the pathogenesis of mantle cell lymphoma (MCL). The genetic change in phosphatidylinositol 3'-kinase catalytic subunit alpha (PIK3CA) in MCL has not been identified.
  13. ncbi Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics
    Pedro Jares
    Haematopathology Section, Laboratory of Pathology, and Genomics Unit, Hospital Clinic, Institut de Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    Nat Rev Cancer 7:750-62. 2007
    b>Mantle cell lymphoma (MCL) is a well-defined lymphoid malignancy characterized by a rapid clinical evolution and poor response to current therapeutic protocols...
  14. ncbi Mantle cell lymphoma: biological insights and treatment advances
    John P Leonard
    Center for Lymphoma and Myeloma, Clinical Research, Division of Hematology Oncology, New York Weill Cornell Medical Center, New York, NY, USA
    Clin Lymphoma Myeloma 9:267-77. 2009
    b>Mantle cell lymphoma (MCL) exhibits considerable molecular heterogeneity and complexity, and is regarded as one of the most challenging lymphomas to treat...
  15. ncbi Concomitant MYC and microRNA cluster miR-17-92 (C13orf25) amplification in human mantle cell lymphoma
    Andrea Rinaldi
    Leuk Lymphoma 48:410-2. 2007
  16. ncbi Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
    Thomas E Witzig
    Mayo Clinic College of Medicine, Stabile 628, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 23:5347-56. 2005
    b>Mantle cell lymphoma (MCL) is characterized by a t(11;14) resulting in overexpression of cyclin D1 messenger RNA...
  17. pmc Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma
    Violetta V Leshchenko
    Albert Einstein Cancer Center, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA
    Blood 116:1025-34. 2010
    b>Mantle cell lymphoma (MCL) is a mostly incurable malignancy arising from naive B cells (NBCs) in the mantle zone of lymph nodes...
  18. ncbi Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis
    Catherine Thieblemont
    Service d Hematologie, Centre Hospitalier Lyon Sud, Pierre Benite, France
    Blood 103:2727-37. 2004
    ..subtypes being small lymphocytic lymphoma (SLL), splenic marginal zone B-cell lymphoma (MZL), and mantle cell lymphoma (MCL)...
  19. ncbi Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma
    Owen A O'Connor
    Department of Medicine, Lymphoma and Developmental Chemotherapy Services, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:676-84. 2005
    ..To determine the antitumor activity of the novel proteasome inhibitor bortezomib in patients with indolent and mantle-cell lymphoma (MCL)...
  20. ncbi Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo
    Liang Zhang
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Am J Hematol 84:553-9. 2009
    ..induction of apoptosis and antibody-dependent cell-mediated cytotoxicity (ADCC) with clinical efficacy in mantle cell lymphoma (MCL). Lenalidomide (LEN), a novel immunomodulatory agent, sensitizes tumor cells and enhances ADCC...
  21. ncbi Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma
    E Drakos
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Leukemia 23:784-90. 2009
    b>Mantle cell lymphoma (MCL) is a clinically aggressive B-cell non-Hodgkin lymphoma characterized by the t(11;14)(q13;q32) and overexpression of cyclin D1...
  22. ncbi JNK is constitutively active in mantle cell lymphoma: cell cycle deregulation and polyploidy by JNK inhibitor SP600125
    Miao Wang
    Department of Pathology and Laboratory Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    J Pathol 218:95-103. 2009
    b>Mantle cell lymphoma (MCL) is characterized by genetic instability and a poor prognosis. Many blastoid variants are (hypo)tetraploid and have an even worse prognosis...
  23. ncbi Bortezomib for the treatment of mantle cell lymphoma
    Robert C Kane
    Division of Drug Oncology Products, Office of Oncology Drug Products, Center for Drug Evaluation and Research, U S Food and Drug Administration, Silver Spring, Maryland 20993 0002, USA
    Clin Cancer Res 13:5291-4. 2007
    To describe the Food and Drug Administration review and marketing approval considerations for bortezomib (Velcade) for the treatment of patients with mantle cell lymphoma.
  24. ncbi Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2
    M Klier
    Institute of Pathology, Helmholtz Center Munich German Research Center for Environmental Health, Neuherberg, Germany
    Leukemia 22:2097-105. 2008
    Cyclin D1 overexpression is the hallmark of mantle cell lymphoma (MCL). However, the importance of cyclin D1 in the maintenance and progression of the disease remains to be defined...
  25. ncbi Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma
    Georg Hess
    Department of Hematology Oncology, Johannes Gutenberg University, Langenbeckstr 1, Mainz, Germany
    J Clin Oncol 27:3822-9. 2009
    ..a specific inhibitor of the mammalian target of rapamycin kinase, has shown clinical activity in mantle cell lymphoma (MCL)...
  26. ncbi The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes
    Paul V Beum
    Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, VA 22908, USA
    J Immunol 176:2600-9. 2006
    ..Antigenic modulation described in previous reports may have been mediated by such shaving, and our findings may have profound implications for the use of mAbs in the immunotherapy of cancer...
  27. ncbi Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma
    Hannes Kaufmann
    University Hospital Vienna, Department of Medicine I, Clinical Division of Oncology, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Blood 104:2269-71. 2004
    ..cells (by rituximab) and the microenvironment (by thalidomide) in 16 patients with relapsed/refractory mantle cell lymphoma (MCL)...
  28. ncbi A novel quantitative PCR of proliferation markers (Ki-67, topoisomerase IIalpha, and TPX2): an immunohistochemical correlation, testing, and optimizing for mantle cell lymphoma
    Helena Brizova
    Department of Pathology and Molecular Medicine, 2nd Medical School, Charles University in Prague and Faculty Hospital in Motol, V Uvalu 84, 150 06, Prague 5, Czech Republic
    Virchows Arch 456:671-9. 2010
    A clinical course of patients with mantle cell lymphoma (MCL) is aggressive, and the disease is rarely curable. Proliferation rate is the most important prognostic factor...
  29. pmc Protein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma
    Robert S Boyd
    Medical Research Council, University of Leicester, Leicester, United Kingdom
    Mol Cell Proteomics 8:1501-15. 2009
    ..shotgun proteomics to identify plasma membrane and lipid raft proteins purified from B cells obtained from mantle cell lymphoma (MCL) patients in leukemic phase...
  30. ncbi Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004
    Yuhong Zhou
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:791-8. 2008
    b>Mantle cell lymphoma (MCL) is a distinct subtype of B-cell non-Hodgkin's lymphoma. To the authors' knowledge, little is known regarding its incidence patterns and associated factors...
  31. ncbi The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak
    Patricia Perez-Galan
    Hematopathology Unit, Department of Pathology, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Spain
    Blood 109:4441-9. 2007
    b>Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma resistant to conventional chemotherapy. The Bcl-2 pathway is deregulated in these tumors and may represent an interesting target for new therapeutic strategies...
  32. ncbi Soluble CD40 ligand induces selective proliferation of lymphoma cells in primary mantle cell lymphoma cell cultures
    N S Andersen
    Leukemia and Lymphoma Marker Laboratory, Department of Hematology, and the Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark
    Blood 96:2219-25. 2000
    ..However, the role of CD40L in the pathogenesis of malignant lymphomas is ambiguous. Primary mantle cell lymphoma (MCL) cells were cultured in the presence of recombinant human CD40L trimer (huCD40LT), and a significant ..
  33. ncbi Expression of sphingosine-1-phosphate receptor 1 in mantle cell lymphoma
    Hirotake Nishimura
    Department of Pathology, Kawasaki Medical School, Kurashiki, Japan
    Mod Pathol 23:439-49. 2010
    ..malignancy cases demonstrated that sphingosine-1-phosphate receptor 1 was expressed on the surface of mantle cell lymphoma cells...
  34. ncbi Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor-kappaB, p53, bax, and p27 levels
    Catherine A Tucker
    Department of Advanced Therapeutics, BC Cancer Research Center, Vancouver, British Columbia, Canada V5Z 1L3
    Mol Cancer Ther 7:749-58. 2008
    ..In this study, we investigated the cell signaling pathways activated in bcl-2-overexpressing human mantle cell lymphoma cell lines (JVM-2 and Z-138) that have been treated with oblimersen, a molecular gene silencing strategy ..
  35. ncbi Mantle cell lymphoma: transcriptional regulation by microRNAs
    L Di Lisio
    Molecular Pathology Programme, Spanish National Cancer Research Centre CNIO, Madrid, Spain
    Leukemia 24:1335-42. 2010
    b>Mantle cell lymphoma (MCL) pathogenesis is still partially unexplained...
  36. ncbi Investigatory and analytical approaches to differential gene expression profiling in mantle cell lymphoma
    Ying Zhu
    Departments of Pathology and Medical Genetics, Haartman Institute and Helsinki University Central Hospital, Laboratory of Computer and Information Science, Helsinki University of Technology, Helsinki, Finland
    Br J Haematol 119:905-15. 2002
    b>Mantle cell lymphoma (MCL) is a non-Hodgkin's lymphoma of B-cell lineage. The blastoid variant of MCL, characterized by high mitotic rate, is clinically more aggressive than common MCL...
  37. ncbi Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications
    Lan V Pham
    Department of Hematopathology, Unit 54, The University of Texas of M D Anderson Cancer Center, Houston, Texas 77030, USA
    Mol Cancer Ther 9:2026-36. 2010
    b>Mantle cell lymphoma (MCL) is an aggressive histotype of B-cell non-Hodgkin lymphoma that has increased in incidence over the past few decades and is incurable, usually poorly responsive to standard chemotherapy combinations, and ..
  38. pmc SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype
    Ana Mozos
    Hematopathology Section, Department of Pathology and Hematology, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, University of Barcelona, Spain
    Haematologica 94:1555-62. 2009
    Cyclin D1-negative mantle cell lymphoma is difficult to distinguish from other small B-cell lymphomas. The clinical and pathological characteristics of patients with this form of lymphoma have not been well defined...
  39. ncbi GI manifestations of mantle cell lymphoma
    Chor Sang Chim
    University Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong
    Gastrointest Endosc 58:931-3. 2003
  40. pmc Preclinical activity of 8-chloroadenosine with mantle cell lymphoma: roles of energy depletion and inhibition of DNA and RNA synthesis
    Jennifer B Dennison
    Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 147:297-307. 2009
    ..In the current study, the efficacy of 8-Cl-Ado was evaluated using mantle cell lymphoma (MCL) cell lines: Granta 519, JeKo, Mino, and SP-53...
  41. ncbi Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma
    Sattva S Neelapu
    Experimental and Transplantation Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, Maryland 20892, USA
    Nat Med 11:986-91. 2005
    ..with severe B-cell depletion but normal T cells after CD20-specific antibody-based chemotherapy of mantle cell lymphoma in first remission...
  42. ncbi Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes
    Christian Korz
    Abteilung Molekulare Genetik and Zentrale Einheit Biostatistik, Deutsches Krebsforschungszentrum, Heidelberg, Germany
    Blood 99:4554-61. 2002
    The B-cell lymphoproliferative malignancies B-cell chronic lymphocytic leukemia (B-CLL) and mantle cell lymphoma (MCL) share characteristics, including overlapping chromosomal aberrations with deletions on chromosome bands 13q14, 11q23, ..
  43. ncbi Intraperitoneal application of rituximab in refractory mantle cell lymphoma with massive ascites resulting in local and systemic response
    Martina Crysandt
    Medizinische Klinik IV, Universitaetsklinikum Aachen, RWTH Aachen, Aachen, Germany
    Eur J Haematol 79:546-9. 2007
    ..In mantle cell lymphoma (MCL), follicular lymphoma and diffuse large B-cell lymphoma, rituximab has been used as monotherapy and in ..
  44. ncbi MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma
    Linhua Jin
    Department of Clinical Pathology, Juntendo University School of Medicine, Tokyo, Japan
    Cancer Lett 299:161-70. 2010
    ..synergistic growth-inhibitory effect of an MDM2 inhibitor Nutlin-3 and a proteasome inhibitor bortezomib in mantle cell lymphoma (MCL) cells regardless of TP53 mutant status and innate bortezomib sensitivity...
  45. ncbi Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bcl-2 expression
    Christian Bogner
    IIIrd Department of Medicine, Technical University of Munich, Munich, Germany
    Br J Haematol 148:99-109. 2010
    b>Mantle cell lymphoma (MCL) is an incurable mature B cell proliferation, combining the unfavourable clinical features of aggressive and indolent lymphomas...
  46. ncbi Induction of apoptosis and down regulation of cell cycle proteins in mantle cell lymphoma by flavopiridol treatment
    Girish Venkataraman
    Department of Pathology, Loyola University Medical Center, Maywood, IL 60153, USA
    Leuk Res 30:1377-84. 2006
    Typical mantle cell lymphoma (MCL) is a distinct B-cell non-Hodgkin's lymphoma associated with over-expression of cyclin D1 related to translocation between the IgH and BCL-1 genes...
  47. pmc Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line
    Rong Chen
    Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center and Graduate School of Biomedical Sciences, University of Texas Houston Health Science Center, Houston, Texas 77030, USA
    Cancer Res 70:6587-97. 2010
    ..The present study focuses on evaluating this compound in four proliferating mantle cell lymphoma lines (Jeko-1, Granta 519, Mino, and SP-53)...
  48. ncbi A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma
    Michael Wang
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:2154-60. 2008
    To establish a severe combined immunodeficient (SCID)-hu in vivo mouse model of human primary mantle cell lymphoma (MCL) for the study of the biology and novel therapy of human MCL.
  49. doi Current treatment standards and future strategies in mantle cell lymphoma
    M Dreyling
    Department of Internal Medicine III, University Hospital Grosshadern, Ludwig Maximilians University, Munich, Germany
    Ann Oncol 19:iv41-4. 2008
  50. ncbi Expanding therapeutic options in mantle cell lymphoma
    Andre Goy
    Lymphoma Division, Hackensack University Medical Center, NJ 07601, USA
    Clin Lymphoma Myeloma 7:S184-91. 2007
    b>Mantle cell lymphoma (MCL) still carries a poor prognosis...
  51. ncbi Value of interphase FISH for the diagnosis of t(11:14)(q13;q32) on skin lesions of mantle cell lymphoma
    Pierre Dubus
    Histology and Molecular Pathology Laboratory, University of Bordeaux 2, France
    Am J Clin Pathol 118:832-41. 2002
    The diagnosis of skin lesions of mantle cell lymphoma (MCL) may be difficult at the onset of the disease...
  52. ncbi Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways
    Edgar Gil Rizzatti
    Department of Clinical Medicine, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, SP, Brazil
    Br J Haematol 130:516-26. 2005
    Microarray studies have revealed the differential expression of several genes in mantle cell lymphoma (MCL), but it is unknown which of these differences are dependent on the transformed MCL cell itself or on the tumour microenvironment...
  53. ncbi Spontaneous rupture of the spleen as the presenting feature of the blastoid variant of mantle cell lymphoma
    K D Mason
    Department of Diagnostic Haematology, Royal Melbourne Hospital, Victoria, Australia
    Clin Lab Haematol 25:263-5. 2003
    ..Although rare cases of splenic rupture have been reported in mantle cell lymphoma there has not been a report of the blastoid variant presenting in this manner...
  54. ncbi Expression of Mcl-1 in mantle cell lymphoma is associated with high-grade morphology, a high proliferative state, and p53 overexpression
    Joseph D Khoury
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston 77030, USA
    J Pathol 199:90-7. 2003
    b>Mantle cell lymphoma (MCL) is a distinct type of B-cell non-Hodgkin's lymphoma characterized by the t(11;14)(q13;q32) and cyclin D1 overexpression. Defects in apoptosis may contribute to pathogenesis...
  55. ncbi Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma
    Sara Ek
    Department of Immunotechnology, CREATE Health, Biomedical Center, Lund University, and Department of Pathology, Lund University Hospital, Sweden
    Blood 111:800-5. 2008
    b>Mantle cell lymphoma (MCL) is defined pathologically by the detection of CD20, CD5, and most importantly cyclin D1 (CCND1)...
  56. ncbi Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo
    M Wang
    Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Leukemia 22:179-85. 2008
    b>Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma with poor clinical outcome. Although front therapy induces a high rate of complete remission (CR), relapse is inevitable and new regimens are much needed for relapsed MCL...
  57. ncbi Mantle cell lymphoma in Taiwan: clinicopathological and molecular study of 21 cases including one cyclin D1-negative tumor expressing cyclin D2
    Shih Sung Chuang
    Department of Pathology, Chi Mei Medical Center, Tainan, Taiwan
    Pathol Int 56:440-8. 2006
    b>Mantle cell lymphoma (MCL) is a rare B-cell lymphoma that has never been characterized in Taiwan...
  58. ncbi Primary gastric mantle cell lymphoma in a patient with long standing history of Crohn's disease
    Markus Raderer
    Departments of Internal Medicine 1, Internal Medicine IV, University of Vienna, Vienna, Austria
    Leuk Lymphoma 45:1459-62. 2004
    ..While secondary gastric involvement from nodal mantle cell lymphoma (MCL) or in the course of primary intestinal MCL (lymphomatous polyposis) have been described, primary ..
  59. ncbi Induction of apoptosis in Jeko-1 mantle cell lymphoma cell line by resveratrol: a proteomic analysis
    Daniela Cecconi
    Dipartimento Scientifico e Tecnologico, Laboratorio di Proteomica, University of Verona, Verona, Italy
    J Proteome Res 7:2670-80. 2008
    Therapies for mantle cell lymphoma (MCL) are clinically unsatisfactory, and the search for effective drugs in vitro might foster the evaluation of their activity in vivo...
  60. ncbi Autoimmunity and lymphoma: is mantle cell lymphoma a mistake of the receptor editing mechanism?
    Ricardo Garcia-Munoz
    Department of Hematology Cell Therapy Area, Clinica Universitaria University of Navarra, Pamplona, Navarra, Spain
    Leuk Res 33:1437-9. 2009
    b>Mantle cell lymphoma (MCL) is an aggressive B cell malignancy, which is believed to originate from naïve B cells in the mantle zone of lymph nodes...
  61. ncbi Synchronous primary gastric mantle cell lymphoma and early gastric carcinoma: a case report
    Yosep Chong
    Department of Pathology, Yonsei University Wonju College of Medicine, 162 Ilsan dong, Wonju, Gangwon Do, South Korea
    Pathol Res Pract 204:407-11. 2008
    b>Mantle cell lymphoma (MCL) commonly invades the gastrointestinal (GI) tract. However, primary GI MCL is rare...
  62. ncbi Autoimmune haemolytic anaemia associated with mantle cell lymphoma
    Heather E Eve
    Department of Haematology, Derriford Hospital, Plymouth PL6 8DH, UK
    Int J Hematol 91:322-5. 2010
    ..has been reported in association with all B and T cell non-Hodgkin lymphoma subtypes with the exception of mantle cell lymphoma (MCL)...
  63. pmc Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma
    Lapo Alinari
    Department of Internal Medicine, Division of Hematology and Oncology, Ohio State University, Columbus, Ohio 43210, USA
    MAbs 1:31-40. 2009
    b>Mantle cell lymphoma (MCL) is a distinct histologic subtype of B cell non-Hodgkins lymphoma (NHL) associated with an aggressive clinical course...
  64. pmc BCL6, MUM1, and CD10 expression in mantle cell lymphoma
    Gabriela Gualco
    Consultoria em Patologia, Botucatu, SP, Brazil
    Appl Immunohistochem Mol Morphol 18:103-8. 2010
    b>Mantle cell lymphoma (MCL) characteristically express CD20, CD5, and cyclin-D1, carries the translocation t(11;14) (q13;q32) and typically has no expression of germinal center cell markers...
  65. ncbi Value of CD23 determination by flow cytometry in differentiating mantle cell lymphoma from chronic lymphocytic leukemia/small lymphocytic lymphoma
    J Z Gong
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Am J Clin Pathol 116:893-7. 2001
    b>Mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) share many morphologic and immunophenotypic features...
  66. ncbi Multiple recurrent chromosomal breakpoints in mantle cell lymphoma revealed by a combination of molecular cytogenetic techniques
    Itziar Salaverria
    Department of Pathology, Hematopathology Unit, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    Genes Chromosomes Cancer 47:1086-97. 2008
    b>Mantle cell lymphoma (MCL) is genetically characterized by 11q13 translocations leading to the overexpression of CCND1, and additional secondary genomic alterations that may be important in the progression of this disease...
  67. ncbi Two-dimensional molecular profiling of mantle cell lymphoma
    Francesca Antonucci
    Department of Agricultural and Industrial Biotechnologies, University of Verona, Italy
    Electrophoresis 24:2376-85. 2003
    ..standard two-dimensional (2-D) maps for control, reactive lymph node and non-Hodgkin's lymphoma (mantle cell lymphoma, MCL). Medium sensitivity, mass spectrometry compatible colloidal Coomassie has revealed a total of ca...
  68. pmc Strong lymphoid nuclear expression of SOX11 transcription factor defines lymphoblastic neoplasms, mantle cell lymphoma and Burkitt's lymphoma
    Michael Dictor
    Department of Pathology, Lund University Hospital, Sweden
    Haematologica 94:1563-8. 2009
    We surveyed lymphomas to determine the range of expression of the mantle cell lymphoma-associated SOX11 transcription factor and its relation to cyclin D1.
  69. pmc Differential diagnosis of cyclin D2+ mantle cell lymphoma based on fluorescence in situ hybridization and quantitative real-time-PCR
    Leticia Quintanilla-Martinez
    Institute of Pathology, Eberhard Karls University of Tubingen, Tubingen, Germany
    Haematologica 94:1595-8. 2009
    b>Mantle cell lymphoma is characterized by the t(11;14) chromosomal translocation, resulting in the overexpression of cyclin D1 (CycD1)...
  70. ncbi GSK-3beta inhibition: at the crossroad between Akt and mTOR constitutive activation to enhance cyclin D1 protein stability in mantle cell lymphoma
    Jessica Dal Col
    Cancer Bio Immunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, IRCCS National Cancer Institute, Aviano, PN, Italy
    Cell Cycle 7:2813-6. 2008
    ..This is particularly true for mantle cell lymphoma (MCL) in which cyclin D1 is overexpressed as a consequence of the t(11;14)(q13;q32) translocation...
  71. ncbi Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group
    Olaf Determann
    Department of Pathology, Hematopathology Section and Lymph Node Registry, University Hospital Schleswig Holstein, Campus Kiel, Kiel, Germany
    Blood 111:2385-7. 2008
    Clinical outcome of mantle cell lymphoma (MCL) is highly heterogeneous...
  72. ncbi Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma
    Shishir Shishodia
    Cytokine Research Section, Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Biochem Pharmacol 70:700-13. 2005
    Human mantle cell lymphoma (MCL), an aggressive B cell non-Hodgkin's lymphoma, is characterized by the overexpression of cyclin D1 which plays an essential role in the survival and proliferation of MCL...
  73. ncbi Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma
    Victor Y Yazbeck
    Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Tex 77030, USA
    Exp Hematol 36:443-50. 2008
    To investigate the mechanisms of antiproliferative effect induced by the mammalian target of rapamycin (mTOR) inhibitor temsirolimus in mantle cell lymphoma (MCL).
  74. ncbi In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts
    Faustino Mollinedo
    Instituto de Biologia Molecular, Centro de Investigacion del Cancer, Consejo Superior de Investigaciones Cientificas Universidad de Salamanca, Spain
    Clin Cancer Res 16:2046-54. 2010
    b>Mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) remain B-cell malignancies with limited therapeutic options...
  75. pmc Transvection mediated by the translocated cyclin D1 locus in mantle cell lymphoma
    Hui Liu
    Center for Hematologic Malignancies, Oregon Cancer Institute, Portland, OR 97239, USA
    J Exp Med 205:1843-58. 2008
    In mantle cell lymphoma (MCL) and some cases of multiple myeloma (MM), cyclin D1 expression is deregulated by chromosome translocations involving the immunoglobulin heavy chain (IgH) locus...
  76. ncbi How I treat mantle cell lymphoma
    Michele Ghielmini
    Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
    Blood 114:1469-76. 2009
    b>Mantle cell lymphoma is included in the World Health Organization classification as distinct lymphoma subtype characterized by the t(11;14)(q13;q32) translocation, which results in overexpression of Cyclin D1...
  77. ncbi Mantle cell lymphoma in the orbital and adnexal region
    P Rasmussen
    Department of Neuroscience and Pharmacology, Section of Eye Pathology, University of Copenhagen, Denmark
    Br J Ophthalmol 93:1047-51. 2009
    To characterise clinicopathological features of mantle cell lymphoma (MCL) in the orbital and adnexal region.
  78. ncbi Characterization of 4 mantle cell lymphoma cell lines
    Hesham M Amin
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Arch Pathol Lab Med 127:424-31. 2003
    b>Mantle cell lymphoma (MCL) is a distinct type of B-cell non-Hodgkin lymphoma characterized by t(11;14)(q13;q32) and cyclin D1 overexpression...
  79. ncbi Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma
    Ulrike Heider
    Department of Haematology and Oncology, Charite Universitatsmedizin Berlin, Germany
    Eur J Haematol 80:133-42. 2008
    b>Mantle cell lymphoma (MCL) is an incurable B cell lymphoma, and novel treatment strategies are urgently needed...
  80. ncbi Fibromodulin, an extracellular matrix protein: characterization of its unique gene and protein expression in B-cell chronic lymphocytic leukemia and mantle cell lymphoma
    Eva Mikaelsson
    Immune and Gene Therapy Laboratory, CCK, Department of Oncology, Karolinska University Hospital, Stockholm, Sweden
    Blood 105:4828-35. 2005
    ..chain reaction [RT-PCR]) in all patients with B-CLL (n = 75) and in most (5 of 7) patients with mantle cell lymphoma (MCL). No mutations in the fibromodulin gene were detected...
  81. pmc Mantle cell lymphoma is characterized by inactivation of the ATM gene
    C Schaffner
    Abteilung Organisation komplexer Genome, Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 280, D 69120 Heidelberg, Germany
    Proc Natl Acad Sci U S A 97:2773-8. 2000
    In mantle cell lymphoma (MCL), the translocation t(11;14) is considered the cytogenetic hallmark of the disease...
  82. pmc Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group
    David J Inwards
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Cancer 113:108-16. 2008
    The objective of this study was to test cladribine (2-CDA) alone and in combination with rituximab in patients with mantle cell lymphoma (MCL).
  83. ncbi Expression of STAT3 and its phosphorylated forms in mantle cell lymphoma cell lines and tumours
    Raymond Lai
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Pathol 199:84-9. 2003
    The pathogenesis of mantle cell lymphoma (MCL) is incompletely understood, although cyclin D1 overexpression leading to deregulated cell proliferation is probably important...
  84. ncbi Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways
    Michael Wang
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 109:5455-62. 2007
    ..This study was undertaken to evaluate the therapeutic efficacy of atiprimod on mantle cell lymphoma (MCL) and elucidate the mechanism by which it induces cell apoptosis...
  85. ncbi Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma
    Andrea Rinaldi
    Laboratory of Experimental Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
    Br J Haematol 132:303-16. 2006
    Among B-cell lymphomas mantle cell lymphoma (MCL) has the worst prognosis...
  86. ncbi Mantle cell lymphoma: state-of-the-art management and future perspective
    Oliver Weigert
    Department of Internal Medicine III, University Hospital Grosshadern, Ludwig Maximilians University, Munich, Germany
    Leuk Lymphoma 50:1937-50. 2009
    b>Mantle cell lymphoma (MCL) is a unique subtype of B-cell non-Hodgkin lymphomas (NHL) characterized in almost all cases by the chromosomal translocation t(11;14)(q13;q32) and nuclear cyclin D1 overexpression...
  87. pmc Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma
    Robert W Chen
    Division of Medical Oncology, University of Colorado Denver School of Medicine, Aurora, Colorado, USA
    Blood 112:822-9. 2008
    ..The most well-known mechanism of overexpression is the t(11;14)(q13;q32) translocation found in mantle cell lymphoma (MCL). It has previously been shown that truncated CCND1 mRNA in MCL correlates with poor prognosis...
  88. ncbi Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray
    W K Hofmann
    Division of Hematology and Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, 8700 Beverly Road, Los Angeles, CA 90048, USA
    Blood 98:787-94. 2001
    ..Therefore, the gene expression pattern in lymph node preparations from patients with mantle cell lymphoma (MCL) was compared to the pattern in nonmalignant hyperplastic lymph nodes (HLs)...
  89. pmc Potentiation of cannabinoid-induced cytotoxicity in mantle cell lymphoma through modulation of ceramide metabolism
    Kristin Gustafsson
    Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet and Karolinska University Hospital Huddinge, Stockholm, Sweden
    Mol Cancer Res 7:1086-98. 2009
    Ceramide levels are elevated in mantle cell lymphoma (MCL) cells following treatment with cannabinoids...
  90. ncbi Mantle cell lymphoma in the ocular adnexal region
    Audrey Looi
    Department of Ophthalmology and Visual Sciences, Vancouver General Hospital and University of British Columbia, Vancouver, Canada
    Ophthalmology 112:114-9. 2005
    To study the clinicopathologic features of mantle cell lymphoma (MCL) in the ocular adnexal region.
  91. ncbi Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations
    Sebastian Böttcher
    Second Department of Medicine, Chemnitzstrasse 33, D 24116 Kiel, Germany
    Haematologica 93:551-9. 2008
    The increasing application of multi-color flow cytometry assays for staging and follow-up in mantle cell lymphoma necessitates that the specificity and sensitivity of this technique are evaluated...
  92. ncbi Pathologic splenic rupture as the presentation of mantle cell lymphoma
    A H Strickland
    Clinical Haematology and Medical Oncology Unit; Royal Hobart Hospital, Hobart, Australia
    Leuk Lymphoma 41:197-201. 2001
    ..We report such a case in an 80-year-old man with mantle cell lymphoma (MCL)...
  93. ncbi Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma
    Luca Paoluzzi
    Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York, USA
    Clin Cancer Res 16:554-65. 2010
    ..They are also known to be prodifferentiating. Mantle cell lymphoma (MCL) is an aggressive subtype of non-Hodgkin lymphoma characterized by the t(11;14)(q13;q32) translocation ..
  94. ncbi Bortezomib in mantle cell lymphoma
    K Stephen Suh
    Jurist Research Center, 30 Prospect Avenue, Hackensack NJ 07601, USA
    Future Oncol 4:149-68. 2008
    b>Mantle cell lymphoma (MCL) represents 6% of non-Hodgkin lymphomas, but is one of the most active fields of clinical investigation. Unfortunately, there is still no standard or curative therapy in MCL...
  95. ncbi A chromosomal translocation in cyclin D1-negative/cyclin D2-positive mantle cell lymphoma fuses the CCND2 gene to the IGK locus
    Stefan Gesk
    Blood 108:1109-10. 2006
  96. ncbi Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies
    Bertrand Coiffier
    Hematology Department, Hospices Civils de Lyon, Pierre Benite, France
    Leuk Lymphoma 50:1916-30. 2009
    ..b>Mantle cell lymphoma (MCL) was the first hematologic malignancy in which mTOR inhibition was explored as a treatment strategy, ..
  97. ncbi The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status
    Patricia Perez-Galan
    Hematopathology Unit, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Spain
    Blood 107:257-64. 2006
    ..These findings should be useful to extend the therapeutic strategies in MCL patients and to improve their prognosis...
  98. ncbi CD5-positive mucosa-associated lymphoid tissue (MALT) lymphoma of ocular adnexal origin: usefulness of fluorescence in situ hybridization for distinction between mantle cell lymphoma and MALT lymphoma
    Kazuhiro Tasaki
    Department of Pathology, Fukushima Medical University, School of Medicine, Fukushima, Japan
    Pathol Int 57:101-7. 2007
    ..The differential diagnosis between CD5-positive MALT lymphoma and mantle cell lymphoma (MCL), notably cyclin D1-negative MCL, was difficult because both cases consisted histologically of small ..
  99. pmc Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
    Christian H Geisler
    Rigshospitalet, Copenhagen, Denmark
    Blood 112:2687-93. 2008
    b>Mantle cell lymphoma (MCL) is considered incurable. Intensive immunochemotherapy with stem cell support has not been tested in large, prospective series...
  100. pmc Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study
    Eric D Hsi
    Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH 44195, USA
    Leuk Lymphoma 49:2081-90. 2008
    The proliferation index in mantle cell lymphoma (MCL) has not been validated in the context of aggressive therapy regimens in the rituximab era...
  101. pmc Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group
    Stephen M Ansell
    Division of Hematology, Mayo Clinic College of Medicine and Mayo Foundation, Rochester, Minnesota, USA
    Cancer 113:508-14. 2008
    The objective of this study was to test a low dose of (25 mg weekly) of the mammalian target of rapamycin kinase inhibitor temsirolimus for patients with relapsed mantle cell lymphoma (MCL).

Research Grants62

  1. Antibody-mediated Gene Therapy for the Treatment of Cancer
    TRACY RUTH DANIELS-WELLS; Fiscal Year: 2013
    ..gene therapy approaches for the systemic treatment of aggressive B-cell lymphomas with an emphasis on mantle cell lymphoma (MCL)...
  2. Heat shock protein 90 antagonist-based therapy of mantle cell lymphoma
    Kapil Bhalla; Fiscal Year: 2012
    ..provided by applicant): New treatment strategies are needed to improve the disease free survival in human mantle cell lymphoma (MCL)...
  3. Mechanistic validation of SCF E3 ligase as a cancer and radiosensitizing target
    Yi Sun; Fiscal Year: 2013
    ..general proteasome inhibitor, approved by FDA for the treatment of relapsed/refractory multiple myeloma and mantle cell lymphoma. To this end, we have focused on SCF (Skp1-Cullin-F-box proteins) E3 ubiquitin ligases, also known as CRLs (..
  4. Murine Models for Mantle Cell Lymphoma: The role of tumor initiating cells (TIC)
    Richard J Ford; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Mantle cell lymphoma (MCL) is the most therapy-resistant;B cell, non-Hodgkin's lymphoma (NHL-B) that currently lacks adequate therapy, and is increasing in incidence in the USA...
  5. Molecular mechanisms of B cell malignant transformation
    Ping Xie; Fiscal Year: 2013
    ..of human B lymphoma, including splenic marginal zone lymphoma, B cell chronic lymphocytic leukemia and mantle cell lymphoma, as well as multiple myeloma (MM)...
  6. New Strategies to Decipher the Pathophysiology of Chronic Fatigue Syndrome
    Vincent C Lombardi; Fiscal Year: 2013
    ..cohorts of CFS patients that correlate with distinct disease phenotypes, including the development of mantle cell lymphoma (MCL) in a subgroup of the American cohort...
  7. HTS for Rpn11 chemical probes
    Raymond J Deshaies; Fiscal Year: 2012
    ..inner chamber of the proteasome can stem the progression of human cancers including multiple myeloma and mantle cell lymphoma. In prior work, we discovered that the Rpn11 subunit of the proteasome contains a novel zinc ..
  8. Strategies to improve the adoptive transfer of T cells
    Stanley R Riddell; Fiscal Year: 2013
    ..to express a chimeric antigen receptor specific for ROR1, a surface molecule expressed on human B-CLL and mantle cell lymphoma, and conserved in M. mullata...
  9. Defining molecular biomarkers for CDK4/6-based cancer therapy by RNA sequencing
    CHRISTOPHER EDWARD MASON; Fiscal Year: 2013
    ..provided by applicant): Dysregulation of the cell cycle is a hallmark of human cancer, in particular mantle cell lymphoma (MCL), wherein cyclin D1 is aberrantly expressed due to chromosomal t(11;14) translocation...
  10. Targeting B-cell lymphoma with Leukothera
    Benjamin A Belinka; Fiscal Year: 2013
    ..b>mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and Burkitt lymphoma)...
  11. Altered cellular bioenergetics influences NKT cell mediated responses to Lymphoma
    Tonya J Webb; Fiscal Year: 2012
    ..In this proposal we are focusing on a specific type of NHL, Mantle Cell Lymphoma (MCL), for which there is currently no curative treatment option available...
  12. Targeting Negative Regulatory Pathways for Immunotherapy of B-Cell Lymphomas
    Eduardo M Sotomayor; Fiscal Year: 2013
    ..pathways in the malignant B-cells and/or APCs would trigger an effective and long-lasting immunity against Mantle Cell Lymphoma(MCL), and aggressive and incurable subtype of Non-Hodgkin's lymphomas...
  13. Epigenomic determinants of clinical outcomes in MCL patients treated on E1405
    Samir Parekh; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Mantle cell lymphoma (MCL) is an aggressive form of Non-Hodgkin's lymphoma whose pathogenesis is not clearly understood...
  14. Tageting BAFF and BAFF-Induced Non-Canonical NF-kB Pathways for Enhancing Mantle
    Jianguo Tao; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Mantle cell lymphoma (MCL) is now recognized as a distinct clinicopathologic subtype of B-cell non-Hodgkin's lymphoma (NHL) and still remains incurable with no standard of care for this disease ..
  15. Effects of human SWI/SNF-associated PRMT5 on lymphomagenesis
    SAID SIF; Fiscal Year: 2011
    ..known about the role played by these chromatin-modifying enzymes in human lymphoid malignancies including mantle cell lymphoma (MCL), which remains a fatal disease...
  16. Natural Killer Cell Regulation by PRDM1 and IRF4/8
    KENNETH LYNN WRIGHT; Fiscal Year: 2013
    ..Rutuximab (anti-CD20) therapy induces NK cell mediated ADCC against some lymphomas including Mantle Cell Lymphoma (MCL). However, in MCL current therapies are not successful and the disease remains incurable...
  17. Antigen Discovery and Development of Tumor-Specific Lymphoma Immunotherapy
    Sattva S Neelapu; Fiscal Year: 2010
    ..termed idiotype, can induce tumor-specific immunity in greater than 80% of patients with follicular and mantle cell lymphoma. Furthermore, vaccination was associated with significantly prolonged disease-free survival, suggesting ..
  18. Nuclear Accumulation of Cyclin D1 and Oncogenesis
    JOHN ALAN DIEHL; Fiscal Year: 2013
    ..Of the various cancers in which deregulated cyclin D1 activity is implicated, mantle cell lymphoma (MCL) is one of the most devastating...
  19. Adoptive cell therapy for lymphoma: A study on the role of CD4 memory T cells in
    MATTHEW JORDAN GOLDSTEIN; Fiscal Year: 2011
    ..We are developing this therapy for evaluation in a clinical trial to treat mantle cell lymphoma. A better understanding of donor vaccination and continued validation of in vitro immune assays will impact ..
  20. Rare Protein Detection on Cell Surfaces: Ultrasensitive Detection of B-Cell Chron
    William Soo Hoo; Fiscal Year: 2013
    ..FC methods do not adequately differentiate between B-CLL and other clonal B-cell malignancies such as mantle cell lymphoma and splenic marginal zone lymphoma...
  21. Lymphoma Therapy with Reprogrammed Measles Viruses
    Roberto B Cattaneo; Fiscal Year: 2013
    ..in infecting cells of lymphoma patients, and in reducing xenografts of different lymphoma types, including mantle cell lymphoma. We will test the oncolytic efficacy of sequential application of viruses with alternative envelopes in ..
  22. Alternative Cleavage and Polyadenylation Events as Biomarkers
    Eric J Wagner; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): A hallmark event in the formation of Mantle Cell Lymphoma (MCL) is the translocation of the cyclin D1 gene downstream of the Ig Enhancer resulting in an upregulation of transcription...
  23. Immunotransplant to Treat Lymphoma: Pre-Clinical Model to Clinical Trial Design
    Joshua D Brody; Fiscal Year: 2010
    ..A clinical trial of immunotransplant will bring this more powerful approach to patients with incurable lymphomas. ..
  24. Characterizing Clonogenic Populations in Mantle Cell Lymphoma
    Nami McCarty; Fiscal Year: 2011
    ..In this proposal, we hypothesize that drug-resistant tumor-initiating cells exist in human mantle cell lymphoma (MCLs), and that they have the capacity to initiate the formation and progression of MCLs...
  25. SPORE in Lymphoma
    Steven H Bernstein; Fiscal Year: 2012
    ..of three of the most common non-Hodgkin's lymphomas, namely diffuse large B-cell, follicular and mantle cell lymphoma. We will initially seek to elucidate mechanisms of action and/or resistance both in vitro, and in carefully ..
  26. Immunotransplant to Mantle Cell Lymphoma: Immune Response and Clinical Outcomes
    Joshua D Brody; Fiscal Year: 2013
    b>Mantle cell lymphoma has a poor long-term prognoses. High dose chemotherapy with stem cell transplant prolongs survival, but chemotherapy-resistant lymphoma cells persist, and ultimately cause patients to relapse and succumb to disease...
  27. Immunotherapy of CLL with lentiviral expressed CD40-ligand
    Boro Dropulic; Fiscal Year: 2006
    ..Phase III, this therapy will be commercialized for CLL and possibly other hematological malignancies like mantle cell lymphoma and acute myeloid leukemia...
  28. Nanobiotechnology for the Treatment of Mantle Cell Lymphoma
    Trudy Forte; Fiscal Year: 2009
    b>Mantle cell lymphoma (MCL) is a B-cell malignancy that is characterized by dysregulation of various oncogenes...
  29. Topoisomerase II Site-Directed Alkylation of DNA
    Laurence Hurley; Fiscal Year: 2006
    ..insights into the molecular pharmacology and molecular biology of drug refractory leukemia and low-grade, mantle cell lymphoma, we have devised strategies to selectively target these cancers. The specific aims of this proposal are: 1...
  30. Anti-CD20 CTL for Therapy of Mantle Cell Lymphoma
    Oliver Press; Fiscal Year: 2007
    ..b>Mantle cell lymphoma (MCL) is a discrete entity that has the worst survival of any type of NHL (median 2-3 years)...
  31. Molecular Mechanisms of Lymphomagenesis
    Kevin Mills; Fiscal Year: 2009
    ..Cytogenetic abnormalities affecting chromosomes 4q21 or 11q23 are common in lymphoid malignancies, such as mantle cell lymphoma and preB-ALL, the latter being the most common pediatric malignancy, at nearly 25% of all childhood cancer ..
  32. A Phase I Study of Single Agent Flavopiridol in B-Cell *
    Thomas Lin; Fiscal Year: 2007
    unreadable] DESCRIPTION (provided by applicant): Mantle cell lymphoma (MCL) and indolent B-cell non-Hodgkin's lymphomas (B-NHL) such as follicle center lymphoma are not curable with current therapies, and many patients with ..
  33. PI3K Pathway Inhibitors for Mantle Cell Lymphoma
    Thomas Witzig; Fiscal Year: 2006
    ..b>Mantle cell lymphoma (MCL) is an important type of NHL because it has a very poor prognosis with an overall survival of only 3-4 ..
  34. MOLECULAR PROBES FOR BURKITT'S AND MANTLE CELL LYMPHOMA
    Nallasivam Palanisamy; Fiscal Year: 2001
    ..FISH assays to detect the t(11;14)(q13;q32) and t(8;14)(q24;q32) chromosomal translocations encountered in Mantle Cell Lymphoma and Burkitt's Lymphoma, respectively, for use in cancer cytogenetic reference laboratories.
  35. INTERPLAY OF E PROTEINS AND CYCLIN D1 DEPENDENT KINASES
    DONALD KOHTZ; Fiscal Year: 2001
    ..The spliceform products of the E2A also play a critical role in normal Bell development. Mantle cell lymphoma is associated with a chromosomal translocation that activates expression of the cyclin D1 gene...
  36. Development of a Small Molecule-Targeted Therapy for Mantle Cell Lymphoma
    Manoj Maniar; Fiscal Year: 2008
    unreadable] DESCRIPTION (provided by applicant): Mantle cell lymphoma (MCL) is an aggressive subtype of non-Hodgkin's lymphoma (NHL) that accounts for 5- 8% of all lymphoma cases...
  37. Novel Monoclonal Antibody Therapies for Lymphoma
    John Leonard; Fiscal Year: 2005
    ..It is also expected that this work will significantly contribute to the care of patients with these and other B-cell malignancies. ..
  38. Monoclonal Antibody Therapy for Follicular Lymphoma
    Jonathan Friedberg; Fiscal Year: 2007
    ..abstract_text> ..
  39. The Proteasome as Molecular Target of Grape Polyphenols
    QING PING DOU; Fiscal Year: 2005
    ..abstract_text> ..
  40. BLys inhibition using TACI-Fc in patients with B-bell non-Hodgkins' Lymphoma
    Stephen Ansell; Fiscal Year: 2008
    ..abstract_text> ..
  41. Roles of polymorphic COMT, tea polyphenols and proteasome in cancer prevention
    QING PING DOU; Fiscal Year: 2010
    ..abstract_text> ..
  42. TEA TARGETING PROTEASOME--A ROLE IN CANCER PREVENTION
    QING DOU; Fiscal Year: 2002
    ..A Future Aim is to determine whether in vivo proteasome-inhibitory ability of tea polyphenols is related to their antitumor activity using nude mice bearing human prostate tumors. ..
  43. Mentored Patient-Oriented Research Career Development Aw
    David Rizzieri; Fiscal Year: 2004
    ..These results will lead to future improvements in maximizing the anti-tumor effects of allogeneic therapy, hastening immunologic recovery, and minimizing the toxicity of this procedure. ..
  44. Quantitative RT-PCR: Prediction Lymphoma Transformation
    Kojo Elenitoba Johnson; Fiscal Year: 2005
    ....
  45. OPTIMIZING RADIOIMMUNOTHERAPY FOR NON HODGKIN'S LYMPHOMA
    Ajay Gopal; Fiscal Year: 2005
    ..We anticipate that these interventions will ultimately enhance the prognosis for patients with relapsed lymphoma by increasing the response and survival rates, while simultaneously minimizing toxicities. ..
  46. Defibrotide for the treatment of severe hepatic veno-cc*
    Paul Richardson; Fiscal Year: 2007
    ..Abstract Not Provided ..
  47. PRE-CLINICAL COMBINATION CHEMO- AND RADIOANTIBODY THERAP
    Rhona Stein; Fiscal Year: 2005
    ..2) Therapy-induced changes in marker expression post therapy can be identified clinically in small samples of circulating tumor cells. ..
  48. Nonmyeloablative Allografting for Hematologic Neoplasia
    Michael Maris; Fiscal Year: 2005
    ....
  49. Measurement & modulation of the mutation rate in humans
    David Araten; Fiscal Year: 2007
    ..These studies will begin to elucidate the relationship between f and cancer risk and provide a highly relevant in vitro parameter with which to evaluate chemoprevention. ..
  50. DIFFUSION MRI AS BIOMARKER FOR THERAPY RESPONSE IN BREAST CANCER METASTASES
    Alison T Stopeck; Fiscal Year: 2010
    ....
  51. Prognostic Models in Diffuse Large B-Cell Lymphoma
    Izidore S Lossos; Fiscal Year: 2010
    ..Further, establishment of a paraffin-based RNA prognostic model using the new methodology of RNA extraction could serve as a paradigm for other lymphomas and tumors. ..
  52. Mechanism of mitotic exit in budding yeast
    Raymond Deshaies; Fiscal Year: 2009
    ..Our work may also provide a useful paradigm for understanding how other pathways that employ reversible nucleolar sequestra - such as the ARF-Mdm2- p53 circuit - are regulated. ..
  53. A Genome-Wide Association Study of Non-Hodgkin Lymphoma
    Christine F Skibola; Fiscal Year: 2010
    ..The data generated from this study will provide a framework for further investigation within the NHL consortium, InterLymph. Results will later be combined with that from other InterLymph case-control studies in pooled analyses. ..
  54. Statistical and Computational Methods for Systematically Mining the SNP and Gene
    Zhenqiu Liu; Fiscal Year: 2008
    ..We hope our researches have the impact of encouraging more people to contribute to this challenging problem. [unreadable] [unreadable] [unreadable]..
  55. High-Throughput Campaign to Identify Reversible Small Molecule Inhibitor of p97/C
    Raymond Deshaies; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  56. Regulation of the P13K/AKT pathway in Waldenstrom Macroglobulinemia
    Irene Ghobrial; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  57. Doxorubicin-Immunoconjugate Therapy of Non-Hodgkin's Lymphoma
    Rhona Stein; Fiscal Year: 2008
    ..abstract_text> ..
  58. Dual Proteasome and MAPK Inhibition in Cancer Therapy
    Robert Orlowski; Fiscal Year: 2008
    ..abstract_text> ..
  59. Clinical Activity of 17-AAG in Lymphoma
    Anas Younes; Fiscal Year: 2007
    ..These favorable in vitro anti-tumor activities were observed in mantle cell lymphoma (MCL), anaplastic large cell lymphoma (ALCL) and HL cell lines...
  60. ANTI-CD20 ANTIBODY THERAPY OF NHL-- MECHANISM OF ACTION
    David Maloney; Fiscal Year: 2002
    ..III. Determine the role of the mAb FC region in mediating anti- proliferative effects of anti-CD20 mAbs in xenografts of B cell NHL lines in NOD/SCID mice. ..
  61. Characterization of Methods for Preservation of Phosphoproteins in fixed tissues
    Eric Hsi; Fiscal Year: 2007
    ..Furthermore, control material with defined relative expression levels of many PPs will result from this application and allow laboratories to assess performance of their individual assays. [unreadable] [unreadable] [unreadable]..